Bruce D. Jackson
Stock Analyst at Benchmark
(3.06)
# 2,456
Out of 5,182 analysts
13
Total ratings
53.85%
Success rate
2.64%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Bruce D. Jackson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| UNCY Unicycive Therapeutics | Maintains: Speculative Buy | $21 → $15 | $6.63 | +126.24% | 2 | Apr 6, 2026 | |
| HUMA Humacyte | Downgrades: Speculative Buy | $10 → $1 | $0.65 | +54.94% | 3 | Mar 31, 2026 | |
| GNLX Genelux | Maintains: Speculative Buy | $23 → $20 | $2.54 | +687.40% | 1 | Mar 20, 2026 | |
| HBIO Harvard Bioscience | Maintains: Speculative Buy | $0.6 → $6 | $4.31 | +39.21% | 3 | Mar 16, 2026 | |
| MLSS Milestone Scientific | Maintains: Speculative Buy | $1.25 → $1 | $0.28 | +263.50% | 1 | Nov 20, 2025 | |
| BLTE Belite Bio | Maintains: Buy | $80 → $132 | $172.76 | -23.59% | 1 | Oct 31, 2025 | |
| RVPH Reviva Pharmaceuticals Holdings | Maintains: Speculative Buy | $280 → $140 | $0.77 | +18,060.59% | 1 | Sep 15, 2025 | |
| CLNN Clene | Maintains: Buy | $33 → $31 | $6.11 | +407.36% | 1 | Sep 10, 2025 |
Unicycive Therapeutics
Apr 6, 2026
Maintains: Speculative Buy
Price Target: $21 → $15
Current: $6.63
Upside: +126.24%
Humacyte
Mar 31, 2026
Downgrades: Speculative Buy
Price Target: $10 → $1
Current: $0.65
Upside: +54.94%
Genelux
Mar 20, 2026
Maintains: Speculative Buy
Price Target: $23 → $20
Current: $2.54
Upside: +687.40%
Harvard Bioscience
Mar 16, 2026
Maintains: Speculative Buy
Price Target: $0.6 → $6
Current: $4.31
Upside: +39.21%
Milestone Scientific
Nov 20, 2025
Maintains: Speculative Buy
Price Target: $1.25 → $1
Current: $0.28
Upside: +263.50%
Belite Bio
Oct 31, 2025
Maintains: Buy
Price Target: $80 → $132
Current: $172.76
Upside: -23.59%
Reviva Pharmaceuticals Holdings
Sep 15, 2025
Maintains: Speculative Buy
Price Target: $280 → $140
Current: $0.77
Upside: +18,060.59%
Clene
Sep 10, 2025
Maintains: Buy
Price Target: $33 → $31
Current: $6.11
Upside: +407.36%